Replacing HMG/FSH by low-dose HCG to complete corifollitropin alfa stimulation reduces cost per clinical pregnancy: a randomized pragmatic trial

Low-dose human chorionic gonadotropin supplementation initiated at the onset of ovarian stimulation can improve oocyte quality without impairing endometrial receptivity: Case series

“…[8] Other studies examined the addition of hCG during the middle-late stage of ovarian stimulation. Decleer et al [9] showed that 150 IU hCG per day from day 7 onwards, instead of highly purified HMG for ovarian stimulation, resulted in a significant reduction in the cost of IVF, and the clinical pregnancy rate was 38% higher in the hCG group than that in the HMG group. Madani et al [10] conducted a prospective randomized pilot trial of poor ovarian responders, and used rFSH alone, 100 IU hCG and rFSH, or 200 IU hCG and rFSH, with hCG supplementation started from day 6 of stimulation.…”

Corifollitropin Alfa for Controlled Ovarian Stimulation in Assisted Reproductive Technologies: State of the Art

“… 20 21 Despite the important friendly appeal of reducing the number of injections, barriers related to the high cost of medication for ovarian stimulation in ART remain. In their small RCT, Decleer et al 22 proposed the use of low-dose daily hCG replacing rFSH or hp-HMG, which are often more expensive. They observed a 45% cost reduction of IVF and an at least similar (but apparently higher) pregnancy rate.…”

“…They observed a 45% cost reduction of IVF and an at least similar (but apparently higher) pregnancy rate. 22 At last, Fatemi et al 23 conducted a small proof of concept study to evaluate if corifollitropin alfa would support the same 7-day action on follicular stimulation in a long GnRH agonist protocol (triptorelin initiated in the mid-luteal phase). Ongoing pregnancies were documented in 28 and 33.3% of started cycles for 100 μg and 150μg, respectively.…”